CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

A popular gene-editing technique may unintentionally delete and rearrange DNA bases, according to a new study published in Nature Biotechnology. The study involves the use of CRISPR-Cas9, a system ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Biochemist Jennifer Doudna received the inaugural Kimberly Prize in Biochemistry and Molecular Genetics at the Robert H. Lurie Medical Research Center on Tuesday. The prize will be awarded annually to ...

Two studies published in Nature Medicine June 11 contribute to a small body of literature suggesting cells edited with CRISPR-Cas9 may cause cancer. Here are five things to know about the studies and ...

(Reuters) -The U.S. Food and Drug Administration's staff reviewers on Friday asked the regulator's advisory panel to consider the need for additional studies for Vertex Pharmaceuticals and CRISPR ...

Shares of Intellia Therapeutics lost nearly half their value Monday a serious safety event led the company to temporarily pause a pair of Phase 3 trials testing its gene-editing drug against the rare ...